Since inception of the Summa Health Structural Heart Valve Program in late 2014, our team has performed more than 500 transcatheter structural heart procedures, including aortic valvuloplasty, transcatheter aortic valve replacement (TAVR), aortic valve in valve replacement, transcatheter mitral valve repair (mitral clip), transcatheter mitral valve in valve replacement, and transcatheter ASD/PFO closure.
Eric Devaney, MD, FACS, Chief, Pediatric Cardiothoracic Surgery, and Martin Bocks, MD, FACC, Director of Pediatric Interventional Cardiology, consult on a patient in the UH Rainbow Babies & Children’s Hospital Cardiac Catheterization Suite.
It’s been almost two years since University...
In the first major trial of its kind, Cleveland Clinic researchers used a blinded rechallenge with atorvastatin or placebo to objectively confirm the presence of muscle-related symptoms in patients with a history of intolerance to multiple statins and found that evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, was a more effective option to lower cholesterol than ezetimibe in these patients.
The legacy of pioneering cardiovascular research at Cleveland Clinic is vast and long-standing. Many established researchers are continuing this legacy of cardiovascular research in their own fields at the Clinic. While it is important to recognize the contributions of all of them, due to space limitations this story focuses on only three of them.
Despite substantial improvements in the treatment of cardiovascular disease over the past 25 years, heart disease is still the leading killer of both men and women — accounting for one in every four deaths, according to the CDC.
For most of the 21st century, the focus of cardiology has centered on improving the quality of care and implementing evidence-based clinical guidelines. A recent study suggests those efforts have yielded a string of remarkable successes.
When Cleveland Clinic Children’s opened its Pediatric Heart Center in 1995, the intention was to build a team of cardiologists and cardiothoracic surgeons to rival all others — maybe even those in the Clinic’s adult Heart & Vascular Institute.
Atrial Fibrillation (AFib) is a major health problem in the U.S., where the lifetime risk of developing it is one in four, according to the National Heart, Lung, Blood Institute (NHLBI). By the end of 2020, the NHLBI projects AFib will affect 4.4 million Americans.
When Robert N. Goldstein, MD, FHRS, was recruited by Lake Health to be Director of Cardiac Electrophysiology (EP) in November 2013, the goal was to expand EP services. Less than six months later, the community hospital system now offers advanced tertiary-level EP services and technologies, including advanced cardiac cryoablation, laser lead extraction, subcutaneous implantable cardioverter defibrillator (S-ICD), and insertable cardiac monitor (ICM).
Heart disease is the leading cause of death for women in the United States. Among all U.S. women who die each year, 25 percent die of heart disease, according to the US Department of Health and Human Services, Office on Women’s Health.